Fierce Biotech13h
Arbutus jettisons 57% of staff, ceases in-house research
The restructuring is only the latest round of layoffs to hit Arbutus, after the company shed 40% of its staff and cut back on ...
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation ...
Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 202 ...
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...
AIM ImmunoTech Inc.: AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the ...